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Background: Cannabis is the most widely consumed illicit drug
worldwide and the relation between cannabis smoking and lung
cancer is suggestive, albeit inconclusive.
Method: We conducted three hospital based case-control studies in
Tunisia, Morocco, and Algeria, three areas of high prevalence of
cannabis consumption as well as production. This paper presents the
pooled analysis of these three studies restricted to men with a total
of 430 cases and 778 controls.
Results: Ninety-six percent of the cases and 67.8% of the controls
were tobacco smokers and 15.3% of the cases and 5% of the controls
were ever cannabis smokers. All cannabis smokers were tobacco
users. Adjusting for country, age, tobacco smoking, and occupa-
tional exposure, the odds ratio (OR) for lung cancer was 2.4 (95%
confidence interval CI: 1.6–3.8) for ever cannabis smoking. This
association remained after adjustment for lifetime tobacco packyears
as continuous variable, OR  2.3 (95% CI: 1.5–3.6). The OR
adjusted for intensity of tobacco smoking (cigarette/d) among cur-
rent tobacco smokers and never cannabis smokers was 10.9 (95%
CI: 6.0–19.7) and the OR among current tobacco users and ever
cannabis smokers was 18.2 (95% CI: 8.0–41.0). The risk of lung
cancer increased with increasing joint-years, but not with increasing
dose or duration of cannabis smoking.
Conclusion: Our results suggest that cannabis smoking may be a
risk factor for lung cancer. However, residual confounding by
tobacco smoking or other potential confounders may explain part of
the increased risk.
Key Words: Cannabis, Lung cancer, Maghreb, Tobacco, Pooled
case-control study.
(J Thorac Oncol. 2008;3: 1398–1403)
With 1.18 million deaths in 2002, lung cancer is theleading cause of cancer deaths among men.1 In 2002,
more persons died of lung cancer in the developing countries
than in the developed countries.1 In Northern Africa, the lung
cancer incidence rate was 12.0 per 100,000 men-years in
2002 after adjustment for the age structure of the world
population, where particularly high rates were observed
among men in the Maghreb (Algeria, Morocco, and Tunisia),
with 16.9, 20.1 and 27.8/100,000 men-years, respectively.1
Tobacco smoking is the major cause of lung cancer2
although other factors such as exposure to asbestos and radon
have also been established as risk factors of lung cancer.3 The
role of other smoked products (such as pipe, cigar or narghile) is
recognized4 and some studies have suggested an association
between cannabis smoking and lung cancer.5–7 Two published
studies conducted by our team suggested that consumption of
hashish/kiff with snuff in Morocco8 and cannabis smoking in
Tunisia9 are associated with lung cancer risk (kiff is a mixture of
black tobacco and sieved resin of cannabis).
To further evaluate this association, particularly with
more powerful means of control for potential confounding by
tobacco smoking we pooled the data from the studies con-
ducted in Morocco8 and Tunisia9 with the data from a third,
yet unpublished study conducted in Algeria. The objective of
this pooled analysis was to estimate the risk of lung cancer
associated with cannabis smoking in Maghreb.
PATIENTS AND METHODS
Study Design
Three hospital-based case-control studies conducted in
Morocco,8 Tunisia,9 and Algeria were pooled. The protocols
of the three studies were similar and are briefly presented
below. Except for the unpublished study from Algeria the
detailed methodology is described in the published papers8,9;
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and only briefly summarized here. All studies were approved
by both the local and the International Agency for Research
on Cancer ethical committees.
Morocco
A hospital based case-control study included 118 cases
and 235 controls that were enrolled in the Ibn Rochd Hospital of
Casablanca, Morocco, between January 1996 and January 1998.
Cases were defined as subjects diagnosed with primary incident
lung cancer. All cases were diagnosed radiologically and 77
cases (68%) were histologically confirmed. Two controls were
matched to each case on age (2 years for 62% and 5 years
for 99% of the study population), sex, and place of residence.
Controls were selected in the same hospital and during the same
period as cases and had a diagnosis not related to tobacco consump-
tion. Theywere hospitalizedwith the following conditions: diabetes
(n 54), acute and chronic gastrointestinal illnesses (n 48), acute
or chronic urinary tract diseases (n  21), liver and biliary tract
diseases (n 33), inguinal and abdominal hernias (n 13), ocular
symptoms and diseases (n  27), prostatic disease (n  9), endo-
crine diseases (n 6), other infectious diseases (n 7), circulatory
diseases, such as hypertension (n  12), anemia (n  2), and
osteoarticular diseases (n  3). Women from this study were
excluded from the pooled analysis because of the small number
(four cases and eight controls).
Tunisia
A hospital based case-control study was conducted among
men only, in Tunis, Tunisia between March 2000 and February
2003 and included 149 cases and 188 controls. Cases were
enrolled in the Salah Azaiz Institute (the National Cancer Insti-
tute) and the Ariana hospital. Cases were defined as patients with
primary incident lung cancer with histologic or cytologic con-
firmed diagnosis except for two cases with only a radiologic
diagnosis. Controls were men recruited in the same period in the
Salah Azaiz Institute, the Ariana hospital and the Charles
Nicolle hospital. Hospitalization was for nonmalignant diseases
of the genitourinary system (n  112), endocrine, nutritional,
or metabolic diseases (n  28), blood or circulatory system
disease (n  10), muscular or osteoarticular disease (n 
18), pneumothorax, pleurisy or infectious pneumopathy
(n  10) or other infectious disease (n  9). The diagnosis
for one control is missing. Controls were matched to each
case on age and place of residence.
Algeria
A hospital based case-control study was conducted in
the Wilaya of Setif, Algeria between March 2003 and De-
cember 2004 and included 167 cases and 340 controls. Cases
and controls were enrolled in the University Hospital of Setif.
Cases were defined as men with primary incident lung cancer
and diagnosis was confirmed by histologic or cytologic ex-
amination. Two controls were matched with each case on age
and place of residence. Controls were men recruited in the
same hospital and during the same period as cases, with the
following conditions: cardiovascular disease (n  118), dia-
betes (n  71), chronic or acute disease of the genito-urinary
track (n  49), healthy controls (visitors from patient’s
family) (n  33), chronic or acute gastrointestinal disease
(n  31), infectious disease (n  16) osteoarticular disease,
fracture or trauma (n  12), dermatological disease (n  9),
and various other diseases (n  24).
Instruments
For the three studies, a questionnaire was used to obtain
information about demographic factors, tobacco and cannabis
smoking and occupational exposures (asbestos, nickel, ar-
senic). The questionnaire was administrated by a trained
physician in Arabic language after informed consent was
obtained from each individual. The first questionnaire was
initially designed for the study in Morocco. It was further
improved and questions on quantitative information on can-
nabis smoking were added for the two studies conducted in
Tunisia and Algeria.
Cannabis Smoking
In the study in Morocco the question on cannabis was
an open question: “Have you ever used other smoked prod-
ucts?” The question was amended for the studies in Tunisia and
Algeria and allowed the definition of three categories of canna-
bis smokers: non smoker, former smoker, and current smoker
(see Appendix). Further information on intensity and duration of
cannabis smoke was also collected. Due to the very low number
of self-reports on current cannabis smoking (one control and
three cases from the study in Algeria), cannabis smoking was
defined as never or ever smoking cannabis in lifetime. For the
pooled analyses the information on cannabis smoking was miss-
ing for 27 cases and 23 controls. Based on a conservative
recoding strategy, these subjects were assigned to the never
smokers of cannabis.
The cumulative consumption was assessed in the stud-
ies from Tunisia and Algeria using the variable ‘joint-years.’
It was defined as the number of joints per day multiplied by
the duration of smoking cannabis in years.
Tobacco Smoking
Smoking status was defined using categories of never,
former (stopped smoking at least 1 year before diagnosis for
cases and equivalent period for controls) (see Appendix) and
current smoker. In 3 cases and 6 controls among current
smokers, and 26 cases and 14 controls among former smok-
ers, the numbers of cigarettes per day were not available. The
missing values were recoded using the median value of 20,
estimated from the number of cigarettes smoked per day
among former and current smokers in controls. For 7 cases
and 21 controls, the duration of smoking exposure could not
be calculated due to missing values for age at initiation and
was replaced with a minimum value of 1 year. To estimate
the odds ratio (OR) for different levels of tobacco smoking,
we constructed a five-category variable with the never ex-
posed individuals as the reference category. The other cate-
gories were former smokers, current smokers with the dura-
tion of use less than 25, 25 to 35 and more than 35 years.
Pack-years of tobacco smoking were estimated for former
and current smokers as the product of number of cigarettes
per day divided by 20 and multiplied by the number of years
exposed. When considering pack-years as a continuous vari-
able, a value of zero pack-years was assigned to never
smokers.
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Occupational exposure was determined using an ever/
never-exposed variable. Any individual with a history of
occupational exposure to nickel or asbestos or arsenic was
considered as ever exposed.
Statistical Analysis
Differences in distributions of qualitative variables be-
tween lung cancer cases and controls were tested using the
Fisher’s exact test. The t test was used to compare means of
continuous variables (age only) and the Kruskal-Wallis test to
compare between countries pack-years of tobacco smoked, and
duration and dose of cannabis smoking. Unconditional logistic
regression was performed to estimate the OR of lung cancer in
the separate studies and in the pooled data. Multivariate analyses
were adjusted for age (as a continuous variable), tobacco smok-
ing status in five categories and occupational exposure; in
addition, pooled analyses were adjusted for country. In addition,
all analyses were carried out using complete sets of cases and
controls instead of recoding of missing variables.
Analyses were carried out using SAS version 9.1.
Relative risks of lung cancer were assessed by estimating
ORs and 95% confidence intervals (CI) based on uncondi-
tional logistic regression models.
RESULTS
A total of 430 cases and 755 controls were included in
the pooled analysis. No difference was observed between the
controls of the 3 countries for tobacco smoking duration and
number of pack-years smoked (Table 1). Similarly, no dif-
ference was observed between the controls for duration or
intensity of cannabis smoking in Tunisia and Algeria (p 
0.21 and p  0.75, respectively) (Table 2). Tobacco smoking
was strongly associated with lung cancer risk in a dose
dependant fashion in all three studies (Table 3).
Cannabis smoking was associated with lung cancer risk
with an age-adjusted pooled OR of 3.3 (95% CI: 2.2–5.1).
This association remained with an OR of 2.4 (95% CI:
1.5–3.7) after further adjustment for country, occupational
exposures and tobacco smoking (Table 4). Conducting the
previous analysis with adjustment for tobacco exposure ex-
pressed in lifetime pack-years and entered in the model as a
continuous variable resulted in an adjusted OR of lung cancer
of 2.3 (95% CI: 1.5–3.6) among ever smokers of cannabis
compared with non smokers, with estimates of 2.6 (95% CI:
1.3–5.2) in Morocco, 2.5 (95% CI: 1.2–5.5) in Tunisia, and
2.4 (95% CI: 0.9–6.5) in Algeria.
We conducted a multivariate analysis stratified by to-
bacco and cannabis smoking status and adjusted for age,
occupational exposure, country, and lifetime packyears of
tobacco smoking. Cannabis smoking was associated with
lung cancer risk among former tobacco smokers (OR  11.9;
95% CI: 5.3–26.8) and among current tobacco smokers (18.4
TABLE 1. Description of Case-Control Studies in Morocco, Tunisia and Algeria
Morocco Tunisia Algeria
Cases Controls Cases Controls Cases Controls
(n  114) (n  227) (n  149) (n  188) (n  167) (n  340)
Study period January 1996–January 1998 March 2000–February 2003 March 2003–December 2004
Mean age (std) (yr) 59.6 (11.1) 59.2 (10.9) 57 (11.6) 57 (11.7) 64.9 (11.1) 63.8 (11.5)
Occupational exposuresa 6 (5%) 2 (1%) 12 (8%) 16 (9%) 4 (2%) 16 (5%)
Tobacco smoking
Never 4 (3%) 87 (38%) 7 (4%) 46 (24%) 4 (2%) 112 (33%)
Former 33 (29%) 86 (37%) 31 (20%) 57 (30%) 82 (49%) 156 (46%)
Current (duration)
25 yr 14 (12%) 16 (7%) 12 (8%) 21 (11%) 4 (2%) 10 (3%)
25–35 yr 20 (18%) 16 (7%) 32 (21%) 32 (17%) 16 (10%) 15 (4%)
35 yr 43 (38%) 22 (10%) 67 (45%) 32 (17%) 61 (37%) 47 (14%)
Pack years ever smoked,
median (interquartile range)
40 (26–56) 24 (11–43) 47 (31–64) 28 (13–45) 32 (19–50) 22 (9–42)
Std, standard deviation.
aEver being exposed to asbestos, nickel, or arsenic.
TABLE 2. Cannabis Smoking By Case-Control Status in Morocco, Tunisia and Algeria
Morocco Tunisia Algeria
Cases Controls Cases Controls Cases Controls
(n  114) (n  227) (n  149) (n  188) (n  167) (n  340)
Ever cannabis 26 (23%) 18 (8%) 30 (20%) 12 (6%) 10 (6%) 9 (3%)
Duration in yr; median (interquartile range) n/a n/a 4 (2–6) 4.5 (3–6) 12.5 (9–30) 6 (4–13)
Number of joints per month; median
(interquartile range)
n/a n/a 5 (1–30) 4.5 (1–76) 9 (8–13) 9 (4–60)
n/a, not applicable.
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95% CI: 8.2–41.6) compared with never tobacco and never
cannabis smokers (Table 4).
Compared with never cannabis smokers, the ORs for
cumulative smoking of cannabis was 1.76 (95% CI: 0.81–
3.82) for less than 2 joint-years and 3.44 (95% CI: 1.51–7.86)
for 2 or more than 2 joint-years, respectively. No increased
risk of lung cancer was observed with increasing intensity or
duration of cannabis smoking (OR  0.9 with p  0.29 and
OR  1.1 with p  0.19, respectively).
Using complete sets of cases and controls, the results
were in general very similar to the results above derived from
the dataset with recoding missing data on tobacco and can-
nabis smoking. Additional adjustment for socio economic
status, involuntary smoking or indoor air pollution were
conducted and the pooled ever/never estimates for cannabis
smoking did not change substantially (data not shown). Be-
cause of the small number of never tobacco users, the anal-
ysis was also conducted among tobacco smokers, and the risk
estimate of ever compared with never cannabis smoking was
again similar (OR  2.4; 95% CI: 1.6–3.8).
DISCUSSION
The results of this pooled analysis of three hospital
based case-control studies conducted in Morocco, Tunisia,
and Algeria support a positive association between cannabis
smoking and lung cancer. A 2.4-fold increase in the risk of
lung cancer among men was estimated for ever cannabis
smokers compared with never users after adjustment for age,
tobacco smoking, occupational exposures, and country.
TABLE 3. Age Adjusted Odds Ratiosa and 95% CI for Tobacco and Cannabis Smoking and Lung Cancer in Case Control
Studies in Morocco, Tunisia and Algeria
Morocco
(114 Cases, 227
Controls)
Tunisia
(149 Cases, 188
Controls)
Algeria
(167 Cases, 340
Controls)
Overall
(430 Cases, 755
Controls)
Tobacco exposure
Tobacco smoking
Never 1 (Reference) 1 (Reference) 1. (Reference) 1 (Reference)
Former 8.2 2.8, 24.2 4.9 1.8, 13.1 14.6 5.2, 41.1 8.0 4.6, 14.0
Current (duration)
25 yr 28.8 7.2, 115.3 2.9 1.0, 8.8 12.5 2.6, 59.6 10.1 4.9, 21.1
25–35 yr 33.3 9.6, 115.6 6.3 2.5, 16.2 32.6 9.4, 113.1 17.4 9.2, 32.8
35 yr 39.6 12.8, 122.7 18.0 6.8, 47.5 35.4 12.1, 103.1 27.9 15.6, 49.8
Pack yearsb 1.036 1.026, 1.047 1.029 1.020, 1.039 1.022 1.015, 1.030 1.028 1.023, 1.033
Cannabis exposure
Never 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Ever 3.4 1.8, 6.6 4.0 1.9, 8.3 2.9 1.1, 7.7 3.3 2.2, 5.1
OR, odds ratio; CI, confidence interval.
aOR and corresponding 95% CI were derived from a logistic regression adjusting for age.
bOR for the increase in risk of lung cancer per additional pack year smoked.
TABLE 4. Adjusted Odds Ratios and 95% CI for Cannabis Smoking and Lung Cancer, and Interaction with Tobacco Smoking
Status in Case Control Studies in Morocco, Tunisia and Algeria
Morocco
(114 Cases, 227
Controls)
Tunisia
(149 cases, 188
controls)
Algeria
(167 Cases, 340
Controls)
Overall
(430 Cases, 755
Controls)
Cannabis exposurea
Never 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Ever 2.2 1.1, 4.5 4.1 1.8, 9.0 2.0 0.7, 5.3 2.4 1.5, 3.7
Combined exposureb
Tobacco Cannabis
Never Never 1 (Reference) 1 (Reference) 1. (Reference) 1 (Reference)
Former Never 2.9 0.9, 9.9 1.4 0.5, 4.2 10.6 3.7, 30.9 4.1 2.3, 7.5
Former Ever 15.5 3.7, 65.1 2.1 0.5, 8.1 65.3 11.6, 367.5 11.9 5.3, 26.8
Current Never 15.5 4.7, 51.5 3.2 1.3, 8.2 24.5 8.2, 73.6 11.3 6.2, 20.5
Current Ever 16.3 4.0, 67.1 26.3 4.6, 149.7 12.2 2.0. 73.9 18.4 8.2. 41.6
OR, odds ratio; CI, confidence interval.
aOR were derived from a logistic regression adjusting for age, occupational exposure, country (in pooled analysis) and tobacco in categories of duration of exposure (never,
former, 25 yr, 25–35 yr, 35 yr).
bOR were adjusted for age, occupational exposure, country (in pooled analysis) and lifetime pack-years tobacco smoking.
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Only the two more recent studies (Tunisia and Algeria)
collected information about frequency and duration of can-
nabis smoking and the variability of cannabis smoking was
low, both factors limiting the possibility to detect a statisti-
cally significant exposure-response relationship. Neverthe-
less, our results for joint-years suggest (albeit not statistically
significant) a positive exposure-response relationship. How-
ever, no dose response relationship for duration or intensity
of cannabis smoking was observed. Additional adjustment for
indoor air pollution, involuntary smoking and socio economic
status did not change the estimates. Information to conduct
analyses by lung cancer histology was not available.
The country profiles of Morocco, Tunisia, and Algeria
are similar with regard to their cultural and historical use of
cannabis,10 as well as their tobacco use. The prevalence of
cannabis smoking in 2000 was 7.4% in Morocco according to
the United Nations Office on Drugs and Crime (UNODC)
report11 and was 8% among the controls from Morocco. Data
on cannabis smoking in Algeria and Tunisia were not avail-
able from the UNODC report.
In Morocco, subjects answering “hashish/kiff” to the fol-
lowing open question: “Have you ever used other smoked
products?” were considered as cannabis smokers. Although the
approach for assessing cannabis exposure was less specific and
less detailed in Morocco compared with the two other studies,
the prevalence of cannabis smoking reported from our study is in
agreement with the UNODC figures for Morocco. There was no
evidence that the questionnaire design of the Moroccan study
could have led to serious misclassification of the individuals
with regard to their cannabis smoking.
None of the cases and controls fromMorocco and Tunisia
and only three cases and one control in Algeria reported current
cannabis smoking. In Maghreb, cannabis smoking has been
legal and culturally accepted for almost four centuries, before
recently becoming illegal. Therefore, given the age of the sub-
jects, past consumption of cannabis mostly referred to a legal use
and therefore, we do not expect substantial or differential un-
derreporting. Recent legislation making cannabis illegal probably
resulted in underreporting of current cannabis smoking. Although
Maghreb is like a subcontinent, in our studies Morocco, Algeria,
and Tunisia differed with regard to cannabis smoking. The lower
Algerian consumption of cannabis compared with Tunisia and
Morocco may be explained by the lowest cultivation of cannabis as
well as cultural, political, and religious differences.
The prevalence of tobacco smoking among men in
2000 was 34.5% in Morocco, 46% in Tunisia, and 43.8% in
Algeria according to the World Health Organization Surveil-
lance of Risk Factors Report and the Tobacco Control Coun-
try Profiles.12 It was similar to the prevalence observed in our
studies during the same period in Tunisia (45%) and Morocco
(24%), except for Algeria where it was much lower (22%)
than reported by Surveillance of Risk Factors Report.
In agreement with the literature,2 a higher risk of lung
cancer for tobacco smokers compared with nonsmokers and a
strong dose-response relationship between cumulative smoking
habits and duration of smoking and the risk of lung cancer was
observed. The dose-response relationship for duration of smok-
ing was somewhat weaker in Tunisia. This may be due to some
misclassification of duration of smoking, particularly age at start of
smoking. However, the risk estimate for pack-years of smoking for
Tunisia was similar to those for Morocco and Algeria.
In the three studies, all cannabis smokers were tobacco
smokers and in Maghreb, cannabis is usually smoked mixed
with tobacco or kiff. The mixing of tobacco with cannabis
and the high proportion of tobacco smokers make it difficult
to assess whether the increased lung cancer risk was related to
the effect of cannabis rather than to the effect of the tobacco
smoked with cannabis or tobacco smoking habits.
To explore the role of potential confounding by tobacco
smoking, we conducted several analyses, using different
approaches to adjust for tobacco smoking and the results were
stable across the different analyses. The differences in
changes of risk estimates observed between Morocco and
Algeria versus Tunisia, between the age-adjusted OR for
cannabis smoking (Table 3) and the OR adjusted for age,
occupational exposures and duration of tobacco exposure
(Table 4) (3.4–2.2 and 2.9–2.0 versus 4.0–4.1, respectively)
may indicate residual confounding by duration of tobacco
smoking in Tunisia, which might be due to an underestima-
tion of the dose-response relationship for duration of tobacco
smoking and lung cancer in Tunisia. This difference was no
longer observed when we adjusted for pack-years instead of
duration of tobacco smoking (data not shown).
Our analyses stratified by smoking status were addition-
ally adjusted for duration and intensity of tobacco use. For
smokers of cannabis compared with nonsmokers of cannabis
these results show increased risks for lung cancer among former
and among current tobacco smokers (Table 4). Therefore, we
believe that confounding by tobacco smoking cannot explain the
increased risk of cannabis smoking. The effect of tobacco mixed
and smoked with cannabis, however, cannot be easily disentan-
gled. At least, we can state that the quantity of tobacco mixed
with cannabis in a joint is generally small.
All three studies were hospital based and a potential
selection bias, particularly for controls can not be excluded.
In Algeria the control group included subjects with cardio-
vascular disease entities not related to tobacco and other were
ill defined cardiovascular disease entities where it was not
possible to clearly rule out tobacco-related diseases. We
decided to perform a sensitivity analysis with and without
those controls with ill-defined cardiovascular disease possibly
related to tobacco smoking. Since effect estimates did not
change considerably, we decided to include these controls in the
final analysis. Further, the wide variety of diagnoses among
controls, exclusion of other tobacco-related diseases from con-
trols, the plausible results for tobacco smoking and lung cancer,
and the consistency of effects of cannabis smoking observed
across all three studies argue against a serious selection bias.
Another potential bias may arise from the absence of
histologic confirmation for 43 cases out of 430. However,
most of the cases were histologically confirmed; only 10%
(43 of 430) were radiologically diagnosed without histologic
confirmation, and most of these cases were from Morocco (41
of 43). Our results for cannabis smoking and lung cancer
from Morocco are very similar to the overall results of the
pooled analyses (Tables 3 and 4). Therefore, we do not
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believe that the small percentage of cases without histologic
confirmation could have seriously biased our results. Further, a
sensitivity analysis was conducted using histologically con-
firmed cases only and the results did not differ (data not shown).
We also conducted analyses using complete case and control
data only, i.e., without assigning the missing values for cannabis
user to never cannabis users and the estimates were similar.
Some recent reviews report more frequent abnormal
histopathologic findings among cannabis smokers13 but few
epidemiological studies have investigated the association
between cannabis smoking and the risk of lung cancer. Hsairi
et al.,5 reported on a hospital based case-control study in
Tunisia that the OR of bronchial cancer for cannabis smokers
compared with nonusers, adjusted for age, sex, cigarettes per
day, snuff tobacco and water pipe use was 8.2 (95% CI:
1.3–15.5). In contrast, two large cohort studies in California
did not find a positive association between marijuana smok-
ing and lung cancer;7,14 however, the assessment of marijuana
smoking relied on self-administrated questionnaires, the co-
hort was relatively young and there were no cases of lung
cancer among marijuana smoker who did not smoke tobacco.
Further, marijuana smoking in California was probably less
intense than in Maghreb.15,16
Mechanistically, there is little evidence that9-tetrahydro-
cannabinol (9-THC) which is the main active ingredient of
cannabis, or other cannabinoids have carcinogenic effects.17
9-THC seems to induce an increase of the enzymatic activity of
the cytochrome CYP1A1 in vitro.18 Moreover, several studies
showed that 9-THC and cannabinoids may have anticarcino-
genic effects.19,20 However, products of combustion of organic
matter are known to be the carcinogenic. Furthermore, it has
been demonstrated that the tar level and the pH of marijuana
smoke was much higher than that of tobacco smoke.21
In conclusion, despite the difficulty to completely ex-
clude residual confounding from tobacco, especially that
coming from the cannabis-tobacco mixture in the joint, our
results suggest an association between cannabis smoking and
increased risk of lung cancer in an area of high level of
consumption of cannabis. Future studies, especially among
heavy and long-term smokers of cannabis and among non-
smokers of tobacco would be desirable to further corroborate
our results, but such populations may be difficult to find.
Experimental studies investigating mutagenic and carcino-
genic effects of cannabis smoke may further strengthen the
biologic plausibility of our results.
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APPENDIX. Questions Used to Set the Tobacco and
Cannabis Smoking Status in the Three Studies (Original
Questionnaire in French Translated to English)
Morocco
Tobacco:
Are you currently smoking tobacco cigarette, even only from time to time?
If yes, are you smoking tobacco cigarette daily or less than that?
Have you ever smoked tobacco cigarette regularly in the past?
Cannabis
Have you ever smoke something else than tobacco cigarette?
If yes, can you specify what type of product were you smoking?
Tunisia
Tobacco
Are you currently smoking tobacco cigarette, even only from time to time?
If yes, are you smoking tobacco cigarette daily or less than that?
Have you ever smoked tobacco cigarette regularly in the past?
Cannabis
Are you smoking cannabis (herb, resin or oil)?
In the past, were you smoking cannabis (herb, resin, oil)?
Morocco
Tobacco
Are you currently smoking tobacco cigarette, even only from time to time?
If yes, are you smoking tobacco cigarette daily or less than that?
Have you ever smoked tobacco cigarette regularly in the past?
Cannabis
Are you smoking cannabis (herb, resin or oil)?
In the past, did you smoke cannabis (herb, resin, oil)?
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